Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 90 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Athyros, V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Statins and heart failure.. J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.
Athyros, V. G., Kakafika A. I., Tziomalos K., Papageorgiou A. A., & Karagiannis A. (2008).  Statins for the prevention of first or recurrent stroke.. Curr Vasc Pharmacol. 6(2), 124-33.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  Are statins 'IDEAL' for non-alcoholic fatty liver disease?. Curr Med Res Opin. 30(2), 229-31.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Athyros, V. G., Tziomalos K., Karagiannis A., Anagnostis P., & Mikhailidis D. P. (2010).  Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 11(1), 122-35.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).. Curr Vasc Pharmacol. 12(6), 867-9.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Katsiki N., & Karagiannis A. (2015).  Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease.. Curr Vasc Pharmacol. 13(3), 366-7.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.
Athyros, V. G., Gossios T. D., Tziomalos K., Florentin M., Karagiannis A., & Mikhailidis D. P. (2011).  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Arch Med Sci. 7(6), 1067-75.
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., & Mikhailidis D. P. (2014).  Therapy: Caloric and fat intake in statin users.. Nat Rev Endocrinol. 10(8), 450-1.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Athyros, V. G., Tziomalos K., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2010).  Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol. 25(4), 406-10.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.. J Diabetes Complications. 29(1), 142-5.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2011).  Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.. Open Cardiovasc Med J. 5, 24-34.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές